Teva Eyes ‘80% Of Off-Patent Opportunities’ For Generics And Biosimilars

As Israeli Firm Identifies New Long-Term Financial Targets For 2027

 
• By Dean Rudge
  
Arrows up (Kutsal Lenger/Alamy Stock Photo)
Teva has revealed new five year targets • Source: Shutterstock (Kutsal Lenger / Alamy Stock Phot/Alamy Stock Photo)
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business